Terms: = Germ cell tumor AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1 AND Clinical Outcome
29 results:
1. Whole-exome sequencing reveals mutational profiles of anorectal and gynecological melanoma.
Sun W; Liu K; Zhou H; Zhao F; Dong Y; Xu Y; Kong Y; Wang M; Cheng X; Chen Y
Med Oncol; 2023 Oct; 40(11):330. PubMed ID: 37831226
[TBL] [Abstract] [Full Text] [Related]
2. Molecular Features of Resected Melanoma Brain Metastases, clinical outcomes, and Responses to Immunotherapy.
Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR
JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977
[TBL] [Abstract] [Full Text] [Related]
3. Correlation of Baseline tumor Burden with clinical outcome in Melanoma Patients Treated with Ipilimumab.
Angelova-Toshkina D; Weide B; Tietze LF; Hebst M; Tietze JK
Oncology; 2024; 102(1):76-84. PubMed ID: 37579734
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic biomarkers for survival in mucosal melanoma.
Thierauf JC; Kaluziak ST; Codd E; Dybel SN; Jobbagy S; Purohit R; Farahani AA; Dedeilia A; Naranbhai V; Hoang MP; Fisch AS; Ritterhouse L; Boland GM; Lennerz JK; Iafrate AJ
Pigment Cell Melanoma Res; 2023 Sep; 36(5):378-387. PubMed ID: 37390098
[TBL] [Abstract] [Full Text] [Related]
5. The A to I editing landscape in melanoma and its relation to clinical outcome.
Amweg A; Tusup M; Cheng P; Picardi E; Dummer R; Levesque MP; French LE; Guenova E; Läuchli S; Kundig T; Mellett M; Pascolo S
RNA Biol; 2022 Jan; 19(1):996-1006. PubMed ID: 35993275
[TBL] [Abstract] [Full Text] [Related]
6. PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with clinical outcome.
Lassalle S; Nahon-Esteve S; Frouin E; Boulagnon-Rombi C; Josselin N; Cassoux N; Barnhill R; Scheller B; Baillif S; Hofman P
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33266349
[TBL] [Abstract] [Full Text] [Related]
7. Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients.
Marczynski GT; Laus AC; Dos Reis MB; Reis RM; Vazquez VL
Sci Rep; 2020 Oct; 10(1):18682. PubMed ID: 33122747
[TBL] [Abstract] [Full Text] [Related]
8. Predicting the clinical outcome of melanoma using an immune-related gene pairs signature.
Meng L; He X; Zhang X; Zhang X; Wei Y; Wu B; Li W; Li J; Xiao Y
PLoS One; 2020; 15(10):e0240331. PubMed ID: 33031392
[TBL] [Abstract] [Full Text] [Related]
9. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy.
Seremet T; Jansen Y; Planken S; Njimi H; Delaunoy M; El Housni H; Awada G; Schwarze JK; Keyaerts M; Everaert H; Lienard D; Del Marmol V; Heimann P; Neyns B
J Transl Med; 2019 Sep; 17(1):303. PubMed ID: 31488153
[TBL] [Abstract] [Full Text] [Related]
10. Conjunctival melanoma copy number alterations and correlation with mutation status, tumor features, and clinical outcome.
Kenawy N; Kalirai H; Sacco JJ; Lake SL; Heegaard S; Larsen AC; Finger PT; Milman T; Chin K; Mosci C; Lanza F; Moulin A; Schmitt CA; Caujolle JP; Maschi C; Marinkovic M; Taktak AF; Heimann H; Damato BE; Coupland SE
Pigment Cell Melanoma Res; 2019 Jul; 32(4):564-575. PubMed ID: 30672666
[TBL] [Abstract] [Full Text] [Related]
11. Gynecologic melanomas: A clinicopathologic and molecular analysis.
Udager AM; Frisch NK; Hong LJ; Stasenko M; Johnston CM; Liu JR; Chan MP; Harms PW; Fullen DR; Orsini A; Thomas DG; Lowe L; Patel RM
Gynecol Oncol; 2017 Nov; 147(2):351-357. PubMed ID: 28844540
[TBL] [Abstract] [Full Text] [Related]
12. Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.
Cosgarea I; Ugurel S; Sucker A; Livingstone E; Zimmer L; Ziemer M; Utikal J; Mohr P; Pfeiffer C; Pföhler C; Hillen U; Horn S; Schadendorf D; Griewank KG; Roesch A
Oncotarget; 2017 Jun; 8(25):40683-40692. PubMed ID: 28380455
[TBL] [Abstract] [Full Text] [Related]
13. Congenital melanocytic nevi: update in genetics and management.
Price HN
Curr Opin Pediatr; 2016 Aug; 28(4):476-82. PubMed ID: 27307047
[TBL] [Abstract] [Full Text] [Related]
14. MAP kinase pathway gene copy alterations in nras/BRAF wild-type advanced melanoma.
Orouji E; Orouji A; Gaiser T; Larribère L; Gebhardt C; Utikal J
Int J Cancer; 2016 May; 138(9):2257-62. PubMed ID: 26684394
[TBL] [Abstract] [Full Text] [Related]
15. Analysis of BRAF and nras Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
Mangana J; Cheng PF; Schindler K; Weide B; Held U; Frauchiger AL; Romano E; Kähler KC; Rozati S; Rechsteiner M; Moch H; Michielin O; Garbe C; Hauschild A; Hoeller C; Dummer R; Goldinger SM
PLoS One; 2015; 10(10):e0139438. PubMed ID: 26426340
[TBL] [Abstract] [Full Text] [Related]
16. [Biological role and prognostic significance of genetic alterations in human malignant melanomas].
Vízkeleti L
Magy Onkol; 2015 Sep; 59(3):268-72. PubMed ID: 26339916
[TBL] [Abstract] [Full Text] [Related]
17. TERT promoter mutations in sinonasal malignant melanoma: a study of 49 cases.
Jangard M; Zebary A; Ragnarsson-Olding B; Hansson J
Melanoma Res; 2015 Jun; 25(3):185-8. PubMed ID: 25746036
[TBL] [Abstract] [Full Text] [Related]
18. Association between BRAFV600E and nrasQ61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma.
Wu S; Kuo H; Li WQ; Canales AL; Han J; Qureshi AA
Cancer Causes Control; 2014 Oct; 25(10):1379-86. PubMed ID: 25048604
[TBL] [Abstract] [Full Text] [Related]
19. Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.
Wilson MA; Zhao F; Letrero R; D'Andrea K; Rimm DL; Kirkwood JM; Kluger HM; Lee SJ; Schuchter LM; Flaherty KT; Nathanson KL
Clin Cancer Res; 2014 Jun; 20(12):3328-37. PubMed ID: 24714776
[TBL] [Abstract] [Full Text] [Related]
20. PP6C hotspot mutations in melanoma display sensitivity to Aurora kinase inhibition.
Gold HL; Wengrod J; de Miera EV; Wang D; Fleming N; Sikkema L; Kirchhoff T; Hochman T; Goldberg JD; Osman I; Gardner LB
Mol Cancer Res; 2014 Mar; 12(3):433-9. PubMed ID: 24336958
[TBL] [Abstract] [Full Text] [Related]
[Next]
